DAN Stock Overview
A biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DanCann Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.0008 |
| 52 Week High | DKK 0.012 |
| 52 Week Low | DKK 0.0004 |
| Beta | 2.08 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -84.62% |
| 33 Year Change | -99.83% |
| 5 Year Change | n/a |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| DAN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -1.3% |
| 1Y | -84.6% | -22.0% | 7.4% |
Return vs Industry: DAN underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: DAN underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| DAN volatility | |
|---|---|
| DAN Average Weekly Movement | 44.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DAN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DAN's weekly volatility has increased from 38% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Jeppe Rasmussen | www.dancann.com |
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros.
DanCann Pharma A/S Fundamentals Summary
| DAN fundamental statistics | |
|---|---|
| Market cap | €1.16m |
| Earnings (TTM) | -€7.93m |
| Revenue (TTM) | €1.10m |
1.0x
P/S Ratio-0.1x
P/E RatioIs DAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DAN income statement (TTM) | |
|---|---|
| Revenue | DKK 8.22m |
| Cost of Revenue | DKK 9.64m |
| Gross Profit | -DKK 1.42m |
| Other Expenses | DKK 57.69m |
| Earnings | -DKK 59.11m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 29, 2024
| Earnings per share (EPS) | -0.038 |
| Gross Margin | -17.27% |
| Net Profit Margin | -719.11% |
| Debt/Equity Ratio | 0% |
How did DAN perform over the long term?
See historical performance and comparison